Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topiramate

FDA-approved product (tablet, oral), marketed as Eprontia, Qudexy Xr, Topamax and 3 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Topiramate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Lennox-Gastaut syndrome
  • Migraine disorder
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Topiramate in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topiramate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)

    NCT07655440 · start 2026-07

    Registered record
    Registry ID
    NCT07655440
    Conditions
    Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
    Interventions
    Galcanezumab; Erenumab 70 mg; Eptinezumab; Atogepant; Amitriptyline; Nortriptyline; propranolol; Verapamil SR 120 mg; Candesartan; topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2031-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
    InterventionGalcanezumab; Erenumab 70 mg; Eptinezumab; Atogepant +6 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary Management

    NCT07707544 · start 2026-06-01

    Registered record
    Registry ID
    NCT07707544
    Conditions
    Idiopathic Intracranial Hypertension
    Interventions
    lumbo-peritoneal shunt; Conservative Management: Centered on lifestyle modifications for weight reduction, alongside targeted medical therapies including carbonic anhydrase inhibitors (e.g., acetazolamide) and/or topiramate.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2026-06-01
    Completion
    2026-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Intracranial Hypertension
    Interventionlumbo-peritoneal shunt; Conservative Management: Centered on lifestyle modifications for weight reduction, alongside targeted medical therapies including carbonic anhydrase inhibitors (e.g., acetazolamide) and/or topiramate.
    PhaseNot applicable
    Registry statusActive not recruiting

  • Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care

    NCT06499116 · start 2024-10

    Registered record
    Registry ID
    NCT06499116
    Conditions
    Migraine
    Interventions
    Topiramate; Flunarizine; Amitriptyline; Propranolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-12
    Enrolment
    460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionTopiramate; Flunarizine; Amitriptyline; Propranolol
    PhasePhase 4
    Registry statusNot yet recruiting

  • Lacosamide Versus Topiramate in Migraine

    NCT06243692 · start 2024-02-01

    Registered record
    Registry ID
    NCT06243692
    Conditions
    Migraine Disorders
    Interventions
    Lacosamide 50 MG; Topiramate 50Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-02-01
    Completion
    2025-02-25
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionLacosamide 50 MG; Topiramate 50Mg Tab
    PhasePhase 3
    Registry statusUnknown

  • Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis

    NCT05759845 · start 2022-08-22

    Registered record
    Registry ID
    NCT05759845
    Conditions
    Migraine
    Interventions
    Topiramate 25Mg Tab; Amitriptyline 25 Mg Oral Tablet; topiramate 25mg plus amitriptyline 25mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-08-22
    Completion
    2023-05-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionTopiramate 25Mg Tab; Amitriptyline 25 Mg Oral Tablet; topiramate 25mg plus amitriptyline 25mg
    PhasePhase 4
    Registry statusUnknown

  • Medications After Adolescent Bariatric Surgery

    NCT04572217 · start 2022-06-01

    Registered record
    Registry ID
    NCT04572217
    Conditions
    Pediatric Obesity
    Interventions
    Topiramate; Phentermine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-06-01
    Completion
    2022-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Obesity
    InterventionTopiramate; Phentermine
    PhasePhase 2
    Registry statusWithdrawn

  • Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)

    NCT05263674 · start 2022-02-07

    Registered record
    Registry ID
    NCT05263674
    Conditions
    Non-Convulsive Status Epilepticus
    Interventions
    Rapid sedation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-02-07
    Completion
    2028-12-31
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Convulsive Status Epilepticus
    InterventionRapid sedation
    PhasePhase 3
    Registry statusRecruiting

  • Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

    NCT05756621 · start 2022-01-15

    Registered record
    Registry ID
    NCT05756621
    Conditions
    Status Epilepticus; Cardiac Arrest
    Interventions
    Ketamine; Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-15
    Completion
    2025-12-31
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatus Epilepticus; Cardiac Arrest
    InterventionKetamine; Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
    PhaseNot recorded
    Registry statusCompleted

  • Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)

    NCT02878798 · start 2018-02-12

    Registered record
    Registry ID
    NCT02878798
    Conditions
    Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
    Interventions
    topiramate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-02-12
    Completion
    2021-09-28
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
    Interventiontopiramate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Individualized Obesity Pharmacotherapy

    NCT03374956 · start 2017-12-11

    Registered record
    Registry ID
    NCT03374956
    Conditions
    Obesity
    Interventions
    Phentermine-Topiramate; Liraglutide; Naltrexone/bupropion; Phentermine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-11
    Completion
    2022-05-26
    Enrolment
    193

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionPhentermine-Topiramate; Liraglutide; Naltrexone/bupropion; Phentermine
    PhasePhase 3
    Registry statusCompleted

  • Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy

    NCT03307863 · start 2017-11-01

    Registered record
    Registry ID
    NCT03307863
    Conditions
    Contraception; Drug Interactions
    Interventions
    Carbamazepine-Implant; Topiramate-Implant; Implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2017-11-01
    Completion
    2028-11-30
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception; Drug Interactions
    InterventionCarbamazepine-Implant; Topiramate-Implant; Implant
    PhasePhase 4
    Registry statusSuspended

  • Efficacy and Safety of Danzhen

    NCT02645370 · start 2016-02

    Registered record
    Registry ID
    NCT02645370
    Conditions
    Migraine
    Interventions
    Danzhen; Topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-02
    Completion
    Not recorded
    Enrolment
    3,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionDanzhen; Topiramate
    PhasePhase 1
    Registry statusUnknown

  • Clinical Experience With Transcutaneous Supraorbital Nerve Stimulation in Refractory Migraine

    NCT03125525 · start 2016-01-01

    Registered record
    Registry ID
    NCT03125525
    Conditions
    Migraine
    Interventions
    Cefaly device
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-01-01
    Completion
    2016-06-30
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionCefaly device
    PhaseNot recorded
    Registry statusCompleted

  • Migraine Treatment in ED

    NCT02643719 · start 2015-12

    Registered record
    Registry ID
    NCT02643719
    Conditions
    Migraine
    Interventions
    Relaxation Therapy; Topiramate; Standard of Care; Abortive Medication (Naproxen and Sumatriptan)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2015-12
    Completion
    2017-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRelaxation Therapy; Topiramate; Standard of Care; Abortive Medication (Naproxen and Sumatriptan)
    PhaseNot applicable
    Registry statusWithdrawn

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated